HOME >> BIOLOGY >> NEWS
Your heart is being closely watched while you're asleep

IF YOU thought sleep is when you really relax, think again. Scientists have discovered that the heart comes under especially close control during sleep. Their findings suggest that sleep may play a role that until now has remained hidden.

Scientists now know that the heartbeat is far more complex and irregular than once supposed (New Scientist, 3 January 1998, p 20). The signals that control a healthy heartbeat contain many different frequency components, and this leads to a highly complex pattern of intervals between beats.

The gaps between heartbeats are "anti-correlated": if the heart speeds up over a short sequence of beats, it will slow down again over the next few beats. More importantly, the pattern of these speed-up/slow-down events can be seen on both short and long timescales: it looks the same over a few beats as it does for a thousand beats. In other words, the heartbeat has a fractal pattern.

An international team led by Plamen Ivanov of the physics department at Boston University decided to compare how the fluctuations in the interval between beats varied between day and night. The results surprised them: during the supposedly relaxed state of sleep, the intervals between heartbeats fluctuated much more strongly, but were brought under control more quickly, showing that the heart is under much closer control during sleep. "It was totally counterintuitive," says Ivanov.

The team initially thought the difference might come about because the body is resting during sleep. Physical activity tends to cause changes in the heartbeat, which would lead to more fluctuations and give the appearance that the heart had less control. But a marked difference remained even when these external influences were taken into account.

The researchers then compared their results with heart data from the cos-monauts on Mir. "It was interesting to compare them with the cosmonauts who were doing something different under different conditions," says L
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-0-20-7331-2751
New Scientist
30-Nov-1999


Page: 1 2

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Screen siblings, parents of infants with severe heart abnormalities
3. Recent evolution at a single gene may have brought down heart disease risk in some human groups
4. How do you mend a broken heart?
5. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Putting energy into heart protection
8. Rare mutations can significantly increase risk factor for heart disease
9. Smart gene therapy protects against damage from heart attack
10. University of Pittsburgh medical center among first to implant heart assist device
11. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Your heart being closely watched while you asleep

(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: